SEC Comment Letter 0000000000-22-013164 to Compass Therapeutics, Inc. (CMPX) (CIK 0001738021) (CMPX)
Compass Therapeutics, Inc. (CMPX) (CIK 0001738021)
Date: Dec. 7, 2022 · CIK: 0001738021 · Accession: 0000000000-22-013164
AI Filing Summary & Sentiment
File numbers found in text: 333-268652
Letter
United States securities and exchange commission logo December 7, 2022 Thomas Schuetz Chief Executive Officer Compass Therapeutics, Inc. 80 Guest Street Suite 601 Boston, Massachusetts 02135 Re:Compass Therapeutics, Inc. Registration Statement on Form S-3 Filed December 2, 2022 File No. 333-268652 Dear Thomas Schuetz: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dillon Hagius at 202-551-7967 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: James Xu
Show Raw Text
United States securities and exchange commission logo
December 7, 2022
Thomas Schuetz
Chief Executive Officer
Compass Therapeutics, Inc.
80 Guest Street
Suite 601
Boston, Massachusetts 02135
Re:Compass Therapeutics, Inc.
Registration Statement on Form S-3
Filed December 2, 2022
File No. 333-268652
Dear Thomas Schuetz:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Dillon Hagius at 202-551-7967 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: James Xu